Loading
PM8002 is an experimental bispecific antibody from Biotheus in phase 3 trials for small-cell lung cancer, triple-negative breast cancer and neuroendocrine tumours, aimed at PD-L1 and VEGF / VEGFR.
PM8002 (BNT327) is a bispecific antibody developed by Biotheus. Its targets are PD-L1 and VEGF / VEGFR (the sponsor names PD-L1 x VEGF). The sponsor states: Study brief summary states PM8002 is a bispecific antibody targeting PD-L1 and VEGF; no further mechanistic detail given. ClinicalTrials.gov describes the intervention as: PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. It is the investigational product in 8 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06616532 (PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer) and NCT06419621 (PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC), in small-cell lung cancer, triple-negative breast cancer, neuroendocrine tumours, colorectal cancer and non-small-cell lung cancer. The largest, NCT06616532, plans to enrol 404 participants with primary completion expected 2027-01-25. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Study brief summary states PM8002 is a bispecific antibody targeting PD-L1 and VEGF; no further mechanistic detail given. Connects to PD-L1 and VEGF / VEGFR.
1.One arm of PM8002 binds PD-L1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"PM8002" OR ABSTRACT:"PM8002" OR TITLE:"BNT327" OR ABSTRACT:"BNT327" OR TITLE:"Pumitamig" OR ABSTRACT:"Pumitamig") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PM8002, not a curated reading list.
Shares A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer, DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors, BioNTech, Non-small-cell lung cancer and the tag pipeline.
Shares A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer, BioNTech and the tag pipeline.
Shares Small-cell lung cancer, Triple-negative breast cancer (TNBC), Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares BioNTech, Colorectal cancer and the tag pipeline.